Shohreh Teimuri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Shohreh Teimuri has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Aref Hosseini
Institute of Pharmacology, University of Bern, 3010 Bern, Switzerland
1 shared publication - Beat Suter
Affiliation Institute of Cell Biology, University of Bern, Berne, Switzerland
1 shared publication Elahe Ghoveud
Hakim Sabzevari University
1 shared publication- Jafar Vatandoost
Department of Biology, Hakim Sabzevari University, Sabzevar, Iran
1 shared publication - Kamran Ghaedi
Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran
1 shared publication Masaba Baroi Sayor
University of Bern
1 shared publication
Latest Publications
- Open Access
RNA Targets and Physiological Role of Topoisomerase 3β
Topoisomerase 3β (Top3β) works not only on DNA but also RNA. We isolated and identified the naturally cross-linked RNA targets of Drosophila Top3β from an early embryonic stage that contains almost exclusively maternal mRNAs. Favorite targets were longer RNAs, RNAs with many splice sites, and RNAs that become localized in large cells. Demonstrating the importance of its enzymatic activity, Top3β without the hydroxyl group that makes the covalent bond to the RNA, did not allow normal expression and subcellular localization of tested gene products of the identified targets. Top3β is not essential for development to the adult stage but to maintain the morphology of the neuromuscular junction in adult flies and to prevent premature loss of coordinated movement and aging. Alterations in human Top3β have been associated with several neurological diseases and cancers. The homologs of genes and (pre)mRNAs mis-expressed in these conditions show the same characteristics identified in the Drosophila Top3β targets, suggesting that Drosophila could model the function of human Top3β . Indeed, an in vivo test of this model showed that the enzymatic activity of Top3β reduces the neurodegeneration caused by the human (G4C2) 49 RNA. Together, these studies show that Top3β plays important roles in normal gene expression, particularly for large genes and long and complex transcripts that need to be transported and translationally controlled. Its absence stresses the cells, seemingly increasing the chances of contracting various neuronal and neurodegenerative diseases and cancers.
Open AccessRNA Targets and Physiological Role of Topoisomerase 3β
Topoisomerase 3β (Top3β) works not only on DNA but also RNA. We isolated and identified the naturally cross-linked RNA targets of Drosophila Top3β from an early embryonic stage that contains almost exclusively maternal mRNAs. Favorite targets were longer RNAs, RNAs with many splice sites, and RNAs that become localized in large cells. Demonstrating the importance of its enzymatic activity, Top3β without the hydroxyl group that makes the covalent bond to the RNA, did not allow normal expression and subcellular localization of tested gene products of the identified targets. Top3β is not essential for development to the adult stage but to maintain the morphology of the neuromuscular junction in adult flies and to prevent premature loss of coordinated movement and aging. Alterations in human Top3β have been associated with several neurological diseases and cancers. The homologs of genes and (pre)mRNAs mis-expressed in these conditions show the same characteristics identified in the Drosophila Top3β targets, suggesting that Drosophila could model the function of human Top3β . Indeed, an in vivo test of this model showed that the enzymatic activity of Top3β reduces the neurodegeneration caused by the human (G4C2) 49 RNA. Together, these studies show that Top3β plays important roles in normal gene expression, particularly for large genes and long and complex transcripts that need to be transported and translationally controlled. Its absence stresses the cells, seemingly increasing the chances of contracting various neuronal and neurodegenerative diseases and cancers.
- 1 October 2019
- Published by Springer Nature in NeuroMolecular Medicine
- Vol. 22 (1) , 111-120
Potential Biomarker and Therapeutic LncRNAs in Multiple Sclerosis Through Targeting Memory B Cells
Multiple sclerosis (MS) is a chronic autoimmune disease that degenerates the central nervous system (CNS). B cells exacerbate the progression of CNS lesions in MS by producing auto-antibodies, pro-inflammatory cytokines, and presenting auto-antigens to activated T cells. Long non-coding RNAs (lncRNAs) play a crucial role in complex biological processes and their stability in body fluids combined with their tissue specificity make these biomolecules promising biomarker candidates for MS diagnosis. In the current study, we investigated memory B cell-specific lncRNAs located, on average, less than 50 kb from differentially expressed protein-coding genes in MS patients compared to healthy individuals. Moreover, we included in our selection criteria lncRNA transcripts predicted to interact with microRNAs with established involvement in MS. To assess the expression levels of lncRNAs and their adjacent protein-coding genes, quantitative reverse transcription PCR was performed on peripheral blood mononuclear cells samples of 50 MS patients compared to 25 controls. Our results showed that in relapsing MS patients, compared to remitting MS patients and healthy controls, lncRNA RP11-530C5.1 was up-regulated while AL928742.12 was down-regulated. Pearson’s correlation tests showed positive correlations between the expression levels of RP11-530C5.1 and AL928742.12 with PAWR and IGHA2, respectively. The results of the ROC curve test demonstrated the potential biomarker roles of AL928742.12 and RP11-530C5.1. We conclude that these lncRNAs are potential markers for detection of relapsing MS patients.
- 1 October 2019
- Published by Springer Nature in NeuroMolecular Medicine
- Vol. 22 (1) , 111-120
Potential Biomarker and Therapeutic LncRNAs in Multiple Sclerosis Through Targeting Memory B Cells
Multiple sclerosis (MS) is a chronic autoimmune disease that degenerates the central nervous system (CNS). B cells exacerbate the progression of CNS lesions in MS by producing auto-antibodies, pro-inflammatory cytokines, and presenting auto-antigens to activated T cells. Long non-coding RNAs (lncRNAs) play a crucial role in complex biological processes and their stability in body fluids combined with their tissue specificity make these biomolecules promising biomarker candidates for MS diagnosis. In the current study, we investigated memory B cell-specific lncRNAs located, on average, less than 50 kb from differentially expressed protein-coding genes in MS patients compared to healthy individuals. Moreover, we included in our selection criteria lncRNA transcripts predicted to interact with microRNAs with established involvement in MS. To assess the expression levels of lncRNAs and their adjacent protein-coding genes, quantitative reverse transcription PCR was performed on peripheral blood mononuclear cells samples of 50 MS patients compared to 25 controls. Our results showed that in relapsing MS patients, compared to remitting MS patients and healthy controls, lncRNA RP11-530C5.1 was up-regulated while AL928742.12 was down-regulated. Pearson’s correlation tests showed positive correlations between the expression levels of RP11-530C5.1 and AL928742.12 with PAWR and IGHA2, respectively. The results of the ROC curve test demonstrated the potential biomarker roles of AL928742.12 and RP11-530C5.1. We conclude that these lncRNAs are potential markers for detection of relapsing MS patients.